Seres Therapeutics Inc. (NASDAQ:MCRB)’s share price shot up 3.4% during trading on Monday . The company traded as high as $11.57 and last traded at $11.41, with a volume of 427,784 shares. The stock had previously closed at $11.04.

A number of brokerages have recently commented on MCRB. FBR & Co reissued a “buy” rating on shares of Seres Therapeutics in a report on Monday, May 2nd. Canaccord Genuity reissued a “buy” rating on shares of Seres Therapeutics in a report on Sunday, May 29th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a report on Monday, June 13th. Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. Finally, Leerink Swann reissued a “buy” rating and issued a $12.00 price target on shares of Seres Therapeutics in a report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Seres Therapeutics has a consensus rating of “Buy” and a consensus target price of $31.57.

The company’s 50-day moving average is $21.47 and its 200-day moving average is $26.12. The firm’s market cap is $475.23 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.24. The business had revenue of $3 million for the quarter, compared to analyst estimates of $4.20 million. During the same quarter in the prior year, the company earned ($1.45) earnings per share. Seres Therapeutics’s quarterly revenue was up NaN% on a year-over-year basis. On average, equities research analysts forecast that Seres Therapeutics Inc. will post ($2.32) earnings per share for the current year.

In other news, CEO Roger Pomerantz sold 70,951 shares of the business’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $30.51, for a total value of $2,164,715.01. Following the transaction, the chief executive officer now owns 254,643 shares of the company’s stock, valued at $7,769,157.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David N. Cook sold 16,000 shares of the business’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $29.43, for a total transaction of $470,880.00. Following the completion of the transaction, the executive vice president now directly owns 144,673 shares in the company, valued at approximately $4,257,726.39. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Seres Therapeutics stock. Jennison Associates LLC increased its stake in Seres Therapeutics Inc. (NASDAQ:MCRB) by 1.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 398,959 shares of the company’s stock after buying an additional 7,259 shares during the period. Jennison Associates LLC owned about 1.02% of Seres Therapeutics worth $13,999,000 as of its most recent SEC filing.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.